Analysis Note

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

Application

This pharmaceutical secondary standard can also be used as follows:Analysis of omeprazole tablets for the separation and detection of omeprazole and its related impurities by reversed-phase high-performance liquid chromatographic (RP-HPLC) methodDetermination of omeprazole and its 11 related impurities in pharmaceutical formulations by RP-HPLC method based on quality-by-design approach (QbD)Development of an ultra-high performance liquid chromatography-time of flight-mass spectrometry (UHPLC-TOF-MS) based method to estimate omeprazole and its related impurities in pharmaceutical formulationsSeparation and detection of omeprazole and its metabolites in human urine samples by capillary zone electrophoresis (CZE) combined with UV-Visible detectorEstimation of related impurities of omeprazole and domperidone in their combined dosage form using the RP-HPLC method

Footnote

To see an example of a Certificate of Analysis for this material enter LRAC3168 in the slot below. This is an example certificate only and may not be the lot that you receive.

General description

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.It is an impurity of the substituted benzimidazoleR13; omeprazole, that belongs to the class of proton pump inhibitors (PPIs). Omeprazole inhibits the secretion of gastric juice by inhibiting the activity of the enzyme H⁺/K⁺-ATPase (Hydrogen-Potassium Adenosine Triphosphates). Hence it is used widely for the treatment of diseases caused by excess secretion of gastric juices.